Laser-induced transient skin disruption to enhance cutaneous drug delivery.


Journal

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 16 05 2020
revised: 12 08 2020
accepted: 27 08 2020
pubmed: 7 9 2020
medline: 8 7 2021
entrez: 6 9 2020
Statut: ppublish

Résumé

The use of pressure waves (PW) to disrupt the stratum corneum (SC) temporarily is an effective strategy to increase the deposition of drug molecules into the skin. However, given the rather modest outcomes when compared with ablation-assisted drug delivery, its potential has been underestimated. Accordingly, the aim of this study was to examine the impact of Resonant Amplitude Waves (RAWs) on increasing cutaneous delivery. RAW phenomena are triggered by focusing a high-peak-power pulsed laser onto an appropriate transducer structure, under space- and time-controlled resolution. In order to determine the optimal conditions for the generation and use of RAWs, a screening of laser parameters setting and an analysis of different geometries of the impact pattern over diverse materials used as transducers was performed, analyzing the footprint of the RAW waves in an agarose gel. The results obtained were then checked and fine-tuned using human skin samples instead of agarose. Furthermore, ex vivo experiments were carried out to characterize the effect of the RAWs in the cutaneous delivery of diclofenac (DIC) and lidocaine (LID) administered in the form of gels. The application of RAWs resulted in an increased delivery of DIC and LID to the skin, whose intensity was dependent on the composition of the formulation. In fact, the maximum observed for DIC and LID in short-time experiments (39.1 ± 11.1 and 153 ± 16 µg/cm

Identifiants

pubmed: 32891732
pii: S0939-6411(20)30271-X
doi: 10.1016/j.ejpb.2020.08.027
pii:
doi:

Substances chimiques

Anesthetics, Local 0
Lidocaine 98PI200987

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-175

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Sergio Del Río-Sancho (S)

Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Av. Barcelona s/n, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

Diego Pan Delgado (D)

Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Av. Barcelona s/n, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

Germán F de la Fuente (GF)

Instituto de Nanociencia y Materiales de Aragón, CSIC - Universidad de Zaragoza, María de Luna 3, Zaragoza, Spain.

Tomás García-Caballero (T)

Department of Morphological Sciences, School of Medicine, University Clinical Hospital, IDIS, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

Antonio Taboada-Suárez (A)

Department of Plastic Surgery, University Hospital Complex of Santiago de Compostela, A Coruña, Spain.

Noemi Csaba (N)

Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Av. Barcelona s/n, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

Carmen Bao-Varela (C)

UA Microóptica & Óptica GRIN (USC-CSIC), Photonics4 life group, Facultade de Física e Facultade de Óptica e Optometría, Universidade Santiago Compostela, Santiago de Compostela, Spain.

María José Alonso (M)

Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Av. Barcelona s/n, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Electronic address: mariaj.alonso@usc.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH